Arch Biopartners Inc.
Overview
Arch Biopartners Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease, focusing on acute kidney injury (AKI) and chronic kidney disease (CKD). Its lead drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Arch Biopartners Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.